Levi & Korsinsky Alerts Zenas BioPharma Shareholders About Upcoming Class Action Lawsuit Deadline in 2025

Zenas BioPharma Class Action Lawsuit: Key Information for Investors

On May 20, 2025, Levi & Korsinsky, LLP, a well-known law firm specializing in securities litigation, announced a significant update for the investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO). This alert comes ahead of a pivotal deadline for shareholders who may have been impacted by alleged securities fraud associated with the company. Understanding the details and implications of this class action lawsuit is crucial for investors who have faced losses relating to their investment in Zenas BioPharma.

What is the Lawsuit About?

The class action lawsuit has been filed to recover losses for shareholders affected by the alleged fraudulent activities of Zenas BioPharma. The complaint states that the company and its representatives made multiple misleading statements regarding its financial health and prospects. Specifically, the lawsuit accuses the company of overestimating the longevity of its operational funding, which was supposedly to be supported through existing cash reserves and the anticipated proceeds from an initial public offering (IPO) in September 2024.

Investors who acquired shares in accordance with the registration statement and related prospectus during or after the IPO may be eligible to participate in this class-action suit. They are being urged to reach out to Levi & Korsinsky for more information and guidance on how to proceed.

Deadline for Lead Plaintiff Submission

One of the essential elements of this class action suit is the lead plaintiff deadline, which is set for June 16, 2025. Affected investors must act quickly if they wish to request their appointment as lead plaintiffs in the case. It's important to note that serving as a lead plaintiff is not a requirement for recovering losses. Investors can still benefit from the settlement even if they do not take on this leadership role in the lawsuit.

No Cost to Participate

Levi & Korsinsky has made clear that participating in this class action lawsuit will not incur any out-of-pocket expenses for class members. This means that affected shareholders can pursue their claim for compensation without needing to cover legal fees upfront. The firm ensures that there is no obligation on the part of the investors to participate, reinforcing the accessible nature of their services.

Why Choose Levi & Korsinsky?

With a reputation built over 20 years, Levi & Korsinsky has successfully represented shareholders in complex securities litigation, achieving substantial recoveries for clients. The firm ranks among the top securities litigation firms in the United States, as indicated by its consistent inclusion in ISS Securities Class Action Services' Top 50 Report. Their experienced team, consisting of over 70 professionals, is dedicated to advocating for investors’ rights, making them a competent choice for those impacted by the alleged fraud at Zenas BioPharma.

How to Get Involved

Investors who believe they have suffered losses due to Zenas BioPharma's misrepresentations are encouraged to take action. They can submit a claim through the Levi & Korsinsky website or directly contact the firm via email or phone for personalized assistance. The firm's representatives are ready to guide shareholders through the intricacies of the claims process and help them secure their potential compensation.

This class action lawsuit serves as a critical reminder for shareholders about the importance of remaining vigilant and informed regarding their investments. With the deadline for lead plaintiff applications approaching, it is essential for affected investors to act promptly to ensure their voices are heard in this significant legal proceeding.